Monoclonal antibodies for the therapy of cancer (original) (raw)

Grafting of "Abbreviated" Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody

E. Padlan, Ameurfina Santos

The Journal of Immunology, 2002

View PDFchevron_right

Advances in the assessment and control of the effector functions of therapeutic antibodies

Thomas Arroll

Nature Reviews Drug Discovery, 2011

View PDFchevron_right

Antibodies, Fc receptors and cancer

Falk Nimmerjahn

Current Opinion in Immunology, 2007

View PDFchevron_right

Monoclonal Antibodies:A promising treatment for cancer

Alex Lardas

View PDFchevron_right

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

Gianfranco Cocorullo

Expert Opinion on Biological Therapy, 2011

View PDFchevron_right

Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields

John Maher

Frontiers in Immunology

View PDFchevron_right

Cloning, isolation and characterization of human tumor in situ monoclonal antibodies

Jeffry Watkins

Cancer Immunol Immunother, 2002

View PDFchevron_right

Human antibodies as next generation therapeutics

Marc van Dijk

Current Opinion in Chemical Biology, 2001

View PDFchevron_right

Functional Consequences of Insertions and Deletions in the Complementarity-determining Regions of Human Antibodies

Mats Ohlin

Journal of Biological Chemistry, 2002

View PDFchevron_right

Monoclonal Antibodies, Human, Engineered

Tracy Daniels, Gustavo Helguera

View PDFchevron_right

Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent

S. Beiboer

Journal of Molecular Biology, 2000

View PDFchevron_right

Mechanistic considerations for the use of monoclonal antibodies for cancer therapy

Patrick Glassman

Cancer biology & medicine, 2014

View PDFchevron_right

Monoclonal Antibody Therapy for Cancer

Grégory ADAMS

Annual Review of Medicine, 2003

View PDFchevron_right

Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent 1 1 Edited by I. A. Wilson

Rob Roovers

J Mol Biol, 2000

View PDFchevron_right

Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization

Sergey Gorlatov

Advances in Enzyme Regulation, 2008

View PDFchevron_right

Single-domain antibodies as building blocks for novel therapeutics

Serge Muyldermans

Current Opinion in Pharmacology, 2008

View PDFchevron_right

The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions

Carrie Wagner, Harlan Weisman

Molecular Immunology, 1995

View PDFchevron_right

Characterization of a mouse-human chimeric antibody to a cancer-associated antigen

Augusto Barbera

International Journal of Cancer, 1992

View PDFchevron_right

Advances in the applications of monoclonal antibodies in clinical oncology

Stephen Cobbold, Mike Clark

Br. J. Cancer, 1986

View PDFchevron_right

The interactions of therapeutic antibodies with Fc receptors

Marcello Albanesi

Immunology Letters, 2012

View PDFchevron_right

Enhanced binding of low-affinity antibodies interacting simultaneously with targeted cell surface molecules and Fc receptor

Michael Hansen

Tissue Antigens, 2002

View PDFchevron_right

Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens

Richard Cote

Proceedings of the National Academy of Sciences, 1986

View PDFchevron_right

Monoclonal antibodies and therapy of human cancers

Alberto Horenstein

Biotechnology Advances, 2000

View PDFchevron_right

of Multivalent Antibodies Design, Construction, and In Vitro Analyses

jacques gaudreault

2017

View PDFchevron_right

Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy

Ellen Vitetta

Cancer research, 1994

View PDFchevron_right

Monoclonal Antibody

Tapan Dutta

View PDFchevron_right

Therapeutic antibodies: successes, limitations and hopes for the future

Patrick Chames

British Journal of Pharmacology, 2009

View PDFchevron_right

A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies

Patrizia Mondello

Leukemia, 2017

View PDFchevron_right

Description of a New Monoclonal Antibody, FC-2.15, Reactive with Human Breast Cancer and other Human Neoplasias

Laura Bover

The International Journal of Biological Markers, 1994

View PDFchevron_right

Monoclonal antibody therapeutics and apoptosis

Daniel Pereira

Oncogene, 2003

View PDFchevron_right

REVIEW REVIEW Antibodies

Inga-lill Mårtensson

2015

View PDFchevron_right

Development of antibody surrogates for the treatment of cancers and autoimmune disease

Thomas Kodadek

Current Opinion in Chemical Biology, 2010

View PDFchevron_right

Monoclonal Antibody in Quest of Cancer Therapeutics

abdullah saeed

View PDFchevron_right

Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity

nicolas frans

Nature Biotechnology, 2005

View PDFchevron_right

Twenty Years with Monoclonal Antibodies: State of the art-Where do we go?

Rauni Norrlund

Acta Oncologica, 1996

View PDFchevron_right